No safety concerns were identified during the trial, and the company said it intends to publish the full data set and share results during an upcoming medical conference. Moderna's vaccine was 83.7% effective in preventing RSV with two or more symptoms in people ages 60 and older, and 82.4% effective at preventing lower respiratory tract disease with three or more symptoms. The designation is intended to expedite the development and review of drugs for serious or life-threatening conditions, and was based on positive topline data from Moderna's phase 3 clinical trial on the vaccine. Moderna's RSV vaccines for adults ages 60 and older received Breakthrough Therapy Designation from the Food and Drug Administration in late January. Moderna's RSV vaccine performed well in clinical trials and was well tolerated by patients, the note said. While most people recover in a week or two, RSV can be serious, particularly for infants and older adults. The three companies are in a race to approve the world's first vaccine against respiratory syncytial virus, which infects the lungs and respiratory tract and usually causes mild, cold-like symptoms. The company became a household name for its messenger RNA technology, which teaches human cells to produce a protein that initiates an immune response against a particular disease.Ĭowen pointed to the company's potential RSV vaccine, noting that key opinion leaders believe RSV will be a "three-player vaccine market" between Moderna and drugmakers Pfizer and GSK.
#Messenger rna vaccine upgrade
The upgrade comes as Moderna navigates its post-pandemic-era boom driven by its mRNA Covid vaccine. "Moderna's near-to-mid-term valuation is becoming less reliant on the emergence of new COVID variant epidemic waves, and more so on PCV, RSV, and flu." "It's clear that mRNA vaccines could be disruptive to the traditional vaccine market as they can target complex antigens simply and with rapid, cell-free manufacturing that can lead to an approved product in record time," wrote Cowen analysts led by Tyler Van Buren, upgrading the stock from market perform to outperform.
0 kommentar(er)
